Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 361

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy

Richardson, Paul G., Mitsiades, Constantine, Hideshima, Teru, Anderson, Kenneth C. · 2006 · Annual Review of Medicine

Abstract

VELCADE® (bortezomib, Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ) is a first-in-class proteasome inhibitor developed specifically for use as an antineoplastic agent. Inhibition of the proteasome results in disruption of homeostatic mechanisms within the cell that can lead to cell death. Bortezomib's first indication, for the treatment of relapsed myeloma in patients who have received at least two prior treatments and progressed on their previous treatment, was based in part on the magnitude of activity demonstrated in phase II trials. Bortezomib is currently indicated for patients who have received at least one prior therapy in the United States and European Union, although patients in the European Union must have already undergone bone marrow transplantation or be unsuitable for the procedure. A phase III trial demonstrated the superiority of bortezomib over high-dose dexamethasone in response rate, time to progression, and survival in patients with myeloma who had relapsed after 1–3 prior therapies. Clinical development is ongoing to investigate its activity as monotherapy and in combination regimens for the treatment of non-Hodgkin's lymphoma, solid tumors, and earlier presentations of myeloma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev.med.57.042905.122625

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 361

Metadata

Authors
Richardson, P. G., Mitsiades, C., Hideshima, T., & Anderson, K. C.
Venue
Annual Review of Medicine
Published
2006-02-01
Volume
57
Issue
1
Pages
33-47
ISSN
  • 0066-4219 (ISSN-L)
  • 1545-326X
OpenAlex
W2149843709
Cited by
361
References
57
FWCI
3.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. https://app.cochat.ai/papers/10.1146/annurev.med.57.042905.122625
The paper
Richardson, P. G., Mitsiades, C., Hideshima, T., & Anderson, K. C. (2006). Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. Annual Review of Medicine. https://doi.org/10.1146/annurev.med.57.042905.122625

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.